Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Journal of Medical Virology
|
September 26, 2022
Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines
Jie Zhou, Zezhong Liu, Guangxu Zhang, et al.
Biomolecules
|
September 28, 2023
IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies
Xiaojie Su, Ziqi Huang, Wei Xu, et al.
Emerging Microbes & Infections
|
August 3, 2023
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Xinling Wang, Lujia Sun, Zezhong Liu, et al.
Mbio
|
April 8, 2024
Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor
Najing Cao, Yanxing Cai, Xin Huang, et al.
Current Research in Microbial Sciences
|
August 23, 2024
Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation
Lujia Sun, Bo Chen, Xianbo Liu, et al.
International Journal of Molecular Sciences
|
June 10, 2023
A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies
Ling Xu, Chao Wang, Wei Xu, et al.
Viruses
|
March 26, 2022
A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern
Lixiao Xing, Xinfeng Xu, Wei Xu, et al.
Acta Pharmaceutica Sinica. B
|
August 9, 2021
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
Jie Zhou, Wei Xu, Zezhong Liu, et al.
Cell Reports. Medicine
|
March 1, 2024
Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD
Zezhong Liu, Jie Zhou, Weijie Wang, et al.
Medcomm
|
July 8, 2025
Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron Subvariants
Guangxu Zhang, Qian Wang, Kai Ji, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Journal of Medical Virology
|
September 26, 2022
Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines
Jie Zhou, Zezhong Liu, Guangxu Zhang, et al.
Biomolecules
|
September 28, 2023
IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies
Xiaojie Su, Ziqi Huang, Wei Xu, et al.
Emerging Microbes & Infections
|
August 3, 2023
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Xinling Wang, Lujia Sun, Zezhong Liu, et al.
Mbio
|
April 8, 2024
Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor
Najing Cao, Yanxing Cai, Xin Huang, et al.
Current Research in Microbial Sciences
|
August 23, 2024
Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation
Lujia Sun, Bo Chen, Xianbo Liu, et al.
International Journal of Molecular Sciences
|
June 10, 2023
A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies
Ling Xu, Chao Wang, Wei Xu, et al.
Viruses
|
March 26, 2022
A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern
Lixiao Xing, Xinfeng Xu, Wei Xu, et al.
Acta Pharmaceutica Sinica. B
|
August 9, 2021
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
Jie Zhou, Wei Xu, Zezhong Liu, et al.
Cell Reports. Medicine
|
March 1, 2024
Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD
Zezhong Liu, Jie Zhou, Weijie Wang, et al.
Medcomm
|
July 8, 2025
Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron Subvariants
Guangxu Zhang, Qian Wang, Kai Ji, et al.
Page
of 3